A study to investigate safety and efficacy of osimertinib and amivantamab in participants with non-small cell lung cancer with common epidermal growth factor receptor mutations

Trial Identifier: D5162C00052
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: July 2023
Primary Completion Date: October 2027
Study Completion Date: October 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
HK Hong Kong, HK
HK Hong Kong, HK, 150001
HK Hong Kong, HK, HKG
HK Shatin, HK, 00000
KR Anyang-si, KR, 14068
KR Busan, KR, 49241
KR Daegu, KR, 42415
KR Seoul, KR, 5030
KR Seoul, KR, 08308
MY George Town, MY, 10990
MY Kota Bharu, MY, 15586
MY Kuala Lumpur, MY, 59100
MY Kuala Lumpur, MY, 50586
MY Kuantan, MY, 25100
MY Kuching, MY, 93200
SG Singapore, SG, 169610
SG Singapore, SG, 308433
TH Bangkok, TH, 10330
TH Bangkok, TH, 10700
TH Bangkok, TH, 10400
TH Chiang Mai, TH, 50200
TH Songkhla, TH, 90110
TW Kaohsiung, TW, 82445
TW Taichung, TW, 40705
TW Taichung, TW, 404
TW Tainan, TW, 73657
TW Taipei, TW, 10048
TW Taipei City, TW, 110
TW Yunlin, TW, 640